Novel chemotherapy-free approaches including epigenetic regulation via inhibition of the enhancer of zeste homolog 2 (EZH2) with tazemeostat in epithelioid sarcoma, mouse double minute 2 homolog (MDM2) inhibitors, cyclin-dependent kinase (CDK) 4/6 inhibitors or multi-kinase inhibitors, and Poly(ADP-ribose) polymerase (PARP) inhibitors are part of clinical trials or are preserved for specific sarcoma subtypes so far [13,14,15]. This evidence concerns the gene EZH2 and epithelioid sarcoma.